Chronic Neuropathic Pain- Pharmacy Technician


  Credits  1.5

This product is currently out of stock and unavailable.

Despite the availability of new drug therapies, neuropathic pain (NP) continues to pose challenges to patients and practitioners alike. It is often chronic in nature and, in a substantial number of patients, is not relieved by medication. Consequences include diminished mobility and function, lack of sleep, depressed mood, and impaired relationships with family and friends. The full medical and societal burden of NP isn’t clear; however, medical costs are estimated to be 3 times higher than those of patients without NP. The loss of patients’ and/or caregivers' ability to work and the need for additional assistance with tasks of daily living are major societal costs. The prevalence of NP is unknown; estimates place it as low as 1% and as high as 10% in the general population. NP is most commonly seen in patients with diabetic peripheral neuropathy (DPN), postherpetic neuralgia (PHN), radiculopathies (e.g., spinal nerve compression that causes pain in the legs or arms), and nerve trauma. The mainstay of treatment for most types of NP consists of antidepressants, anticonvulsants, topical anesthetics, and opioid analgesics. Only a handful, however, have been FDA approved: gabapentin (Neurontin®, Gralise®), lidocaine 5% patch (Lidoderm®), and capsaicin 8% patch (Qutenza®) for PHN; duloxetine (Cymbalta®) and extended-release tapentadol (Nucynta® ER) for DPN; and pregabalin (Lyrica®) for PHN and DPN. In order to achieve clinically meaningful pain relief, patients commonly require more than one type of medication. Treatment is often complicated by coexisting health conditions, and current guidelines recommend a highly individualized approach to management. Community practitioners can play a key role in helping patients optimize drug therapy and minimize the consequences of NP. This issue briefly reviews NP and the medications recommended for treatment, with a focus on the treatment of DPN and PHN, the most thoroughly studied types of NP.


Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Tech Drug Therapy

Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

Course Accreditation

  • Activity Type:
  • CE Broker
  • Universal Activity Number:
    Pharmacy Technician : 0428-0000-12-012-H01-T
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.